Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study
ConclusionsCabozantinib 60 mg/day has a favorable benefit/risk profile for Japanese patients with advanced HCC who have previously received one or two lines of systemic anticancer therapy including sorafenib. (Clinical trial registration: NCT03586973)
Source: Journal of Gastroenterology - Category: Gastroenterology Source Type: research
More News: Cancer & Oncology | Carcinoma | Clinical Trials | Gastroenterology | Hepatocellular Carcinoma | Japan Health | Liver Cancer | Oral Cancer | Study